Cerevance has said it plans to move on to late-stage trials of its first-in-class Parkinson's disease drug CVN424 after hitting the mark in a phase 2 proof-of-concept study. The Boston-based biotech ...

Laboratory animals are used in biomedical research to study physiological and pathological conditions in living organisms ...